Both in the context of exclusively dietary interventions and after bariatric surgery or treatment with GLP(glucagon-like peptide)-1 analogs, there is not only a reduction in weight, but also a loss of muscle mass to varying degrees. A differentiated clinical examination shows that this loss does not necessarily equate to a functional deterioration.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- AI in neurology
Control instead of a flood of data: AI makes big data and wearables usable
- Participation of the patient
Adherence in psychiatry
- Eosinophilic esophagitis
EoE rarely occurs in isolation
- Lung cancer with EGFR mutation
New perspectives in first-line therapy
- Sleep disorder
Sleep medicine in transition: new goals and a reassessment of old hypnotics
- Ginkgo biloba extract in the Alzheimer's mouse model
Effects on disease-associated microglia subpopulations
- "Patients W.A.I.T Indicator"
Access to medicines – how does Switzerland compare across Europe?
- Osteoporosis